Molecular abnormalities of the B cell in systemic lupus erythematosus are candidates for functional inhibition treatments. (Q38192725)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24588739%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

review article

1 reference

title

Molecular abnormalities of the B cell in systemic lupus erythematosus are candidates for functional inhibition treatments (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24588739%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

systemic lupus erythematosus

1 reference

based on heuristic

inferred from title

author

Stamatis-Nick Liossis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24588739%20AND%20SRC:MED&resulttype=core&format=json

Konstantinos Melissaropoulos

9 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24588739%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Stamatis-Nick C Liossis

1

1 reference

30 August 2017

Konstantinos Melissaropoulos

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

4 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24588739%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24588739%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24588739%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24588739%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

833-840

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24588739%20AND%20SRC:MED&resulttype=core&format=json

Systemic lupus erythematosus.

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Defective B cell tolerance checkpoints in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

The role of B cells in lpr/lpr-induced autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Genetic susceptibility to SLE: recent progress from GWAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

B cell antigen receptor signaling 101.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

B cell receptor and BAFF receptor signaling regulation of B cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Altered B-cell signaling in lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Genetic interdependence of Lyn and negative regulators of B cell receptor signaling in autoimmune disease development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Genetic associations of LYN with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

MicroRNA-30a promotes B cell hyperactivity in patients with systemic lupus erythematosus by direct interaction with Lyn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

TLRs and IFNs: critical pieces of the autoimmunity puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Enhanced phosphoinositide 3-kinase δ activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Colonel Bruton's kinase defined the molecular basis of X-linked agammaglobulinemia, the first primary immunodeficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.894976

10.1517/14656566.2014.894976

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24588739%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference